Pfizer Inc. (NYSE:PFE) Receives Consensus Recommendation of “Hold” from Analysts

Pfizer Inc. (NYSE:PFE) has earned a consensus rating of “Hold” from the twenty-one ratings firms that are covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, fourteen have given a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $28.50.

PFE has been the subject of several research reports. Guggenheim lowered their price objective on shares of Pfizer from $36.00 to $35.00 and set a “buy” rating for the company in a research report on Monday. BMO Capital Markets reduced their target price on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research report on Monday. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. Finally, Wolfe Research restated an “underperform” rating and issued a $26.00 price objective on shares of Pfizer in a research report on Thursday, May 14th.

Hedge Funds Weigh In On Pfizer

Several large investors have recently made changes to their positions in the company. Brighton Jones LLC lifted its holdings in Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after buying an additional 618,117 shares during the period. Revolve Wealth Partners LLC grew its holdings in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after acquiring an additional 2,087 shares during the period. United Bank grew its holdings in Pfizer by 12.4% during the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after acquiring an additional 6,415 shares during the period. Sei Investments Co. raised its position in shares of Pfizer by 31.5% during the 2nd quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock valued at $63,889,000 after acquiring an additional 631,523 shares during the last quarter. Finally, HUB Investment Partners LLC raised its position in shares of Pfizer by 45.3% during the 2nd quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock valued at $2,480,000 after acquiring an additional 31,896 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: A Phase 3 failure in a competing biotech program boosted Pfizer and other rivals, as investors saw a potential competitive benefit for the company. The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions (PFE)
• Positive Sentiment: Market commentary highlighted Pfizer as a discounted value stock, suggesting investors may be attracted to its lower valuation and dividend yield. Abbott Labs Vs. Pfizer: Which Discounted Healthcare Titan Screens as the Bigger Value Trap?
• Positive Sentiment: Pfizer finished the latest session higher even as the broader market declined, reinforcing relative strength in the stock. Pfizer (PFE) Advances While Market Declines: Some Information for Investors
• Neutral Sentiment: Analysts remain broadly cautious, with recent coverage showing an average “Hold” rating on Pfizer, which suggests the market is still waiting for clearer growth catalysts. Pfizer Inc. (NYSE:PFE) Receives Average Rating of “Hold” from Analysts
• Negative Sentiment: BMO Capital Markets cut its price target on Pfizer, signaling somewhat softer expectations for the shares despite keeping an outperform rating. Pfizer price target lowered by BMO Capital Markets
• Negative Sentiment: Guggenheim also trimmed its price target on Pfizer, though it maintained a buy rating, reflecting slightly less upside in the near term. Pfizer price target lowered by Guggenheim

Pfizer Price Performance

Pfizer stock opened at $24.46 on Tuesday. The business’s fifty day moving average is $25.32 and its two-hundred day moving average is $26.18. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The firm has a market cap of $139.41 billion, a P/E ratio of 18.67 and a beta of 0.35. Pfizer has a 52 week low of $23.11 and a 52 week high of $28.75.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. During the same period last year, the company posted $0.92 earnings per share. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts forecast that Pfizer will post 2.96 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is 131.30%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.